Novocure Ltd income statement

In fiscal 2025, Novocure Ltd reported revenue of $655m, up 8.3% on the year before, operating income of −$154m (a -23.5% margin) and net income of −$136m, or −$1.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Novocure Ltd: income statement, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	10	15	33	83	177	248	351	494	535	538	509	605	655	725
Cost of revenue	7	10	21	40	56	80	89	107	115	115	128	137	167	167
Gross profit	3	5	12	37	121	168	263	388	420	423	381	468	488	559
Research and development	35	40	44	41	38	51	79	132	201	206	223	210	225	229
Selling and marketing	16	21	39	59	64	78	97	118	137	174	227	239	240	242
General and administrative	17	24	34	51	59	73	88	107	126	133	164	190	178	212
Operating income	−64	−80	−104	−115	−39	−34	−1	30	−44	−90	−233	−170	−154	−125
Interest expense	13	0	3	7	12	17	15	18	9	8	5	12	22	—
Net interest income	—	—	—	—	—	—	—	—	—	8	—	—	—	—
Income before tax	−77	−80	−107	−121	−48	−46	−9	18	−52	−82	−192	−131	−136	−131
Income tax	0	0	4	10	13	18	−2	−2	6	11	15	37	−0	−9
Net income	−77	−81	−112	−132	−62	−64	−7	20	−58	−93	−207	−169	−136	−122
Diluted EPS	−$6.73	−$6.46	−$3.67	−$1.54	−$0.70	−$0.69	−$0.07	$0.18	−$0.56	−$0.88	−$1.95	−$1.56	−$1.22	−$1.06
Diluted shares (average)	11m	12m	30m	86m	89m	92m	97m	109m	103m	105m	106m	108m	111m	115m
EBITDA	−63	−78	−101	−110	−32	−25	8	40	−34	−79	−222	−159	−139	−107

US$ millions unless shown otherwise. Fiscal quarters.

Novocure Ltd: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	161	155	159	167	174	174	184	193
Cost of revenue	33	39	41	45	42	39	41	45
Gross profit	128	116	117	122	132	135	142	149
Research and development	51	54	56	54	61	58	51	58
Selling and marketing	67	56	57	59	69	58	62	53
General and administrative	72	45	44	46	43	86	40	44
Operating income	−63	−38	−40	−36	−40	−67	−11	−6
Income before tax	−55	−30	−35	−30	−41	−69	−12	−8
Income tax	11	4	5	7	−16	2	3	3
Net income	−66	−34	−40	−37	−24	−71	−16	−10
Diluted EPS	−$0.61	−$0.31	−$0.36	−$0.33	−$0.22	−$0.62	−$0.13	−$0.09
EBITDA	−60	−35	−36	−32	−36	−63	−6	−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GKOS vs NVCR NVCR vs TMDX MYGN vs NVCR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Novocure Ltd's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Novocure Ltd.